Analyst Research

Report Title Price
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : Pechala's Reports
Provider : Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CASI Pharmaceuticals Inc receives U.S. Orphan Drug Designation for use of ENMD-2076 to treat Hepatocellular Carcinoma

Monday, 7 Jul 2014 07:00am EDT 

CASI Pharmaceuticals Inc:Companies orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from U.S. Food and Drug Administration (FDA) for treatment of hepatocellular carcinoma (HCC).Orphan Drug designation is granted by FDA office of orphan products development.Designation entitles sponsor to seven years of market exclusivity as well as opportunities for additional funding and expert protocol assistance. 

Company Quote

-0.01 -0.97%
4:00pm EDT